Literature DB >> 1982773

Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.

C G Regårdh1, P Lundborg, M Gabrielsson, A Heggelund, K Kylberg-Hanssen.   

Abstract

The pharmacokinetics of pafenolol were studied in eight young healthy individuals. The doses were 10 mg iv and 40 mg orally. Each dose was labeled with 100 microCi [3H]pafenolol. The plasma concentration-time curve of the oral dose exhibited dual maxima. The second peak was about four times higher than the first one. Maximum concentrations were attained after 0.9 +/- 0.2 and 3.7 +/- 0.6 hr. The mean bioavailability (F) of the oral dose was 27.5 +/- 15.5%. The reduction in F was due mainly to incomplete gastrointestinal absorption. The drug was rapidly distributed to extravascular sites; t1/2 lambda 1 was 6.6 +/- 1.8 min. The volumes of distribution were Vc = 0.22 +/- 0.08 liter/kg, Vss = 0.94 +/- 0.17 liter/kg, and Vz = 1.1 +/- 0.16 liters/kg. The iv dose of pafenolol was excreted in unchanged form in the urine to 55.6 +/- 5.1% of the given dose and in the feces to 23.8 +/- 5.7% within 72 hr. The corresponding recoveries of the oral dose were 15.8 +/- 5.9 and 67.0 +/- 10.2%, respectively. About 10% of both doses was recovered as metabolites in the excreta. Approximately 6% of the oral dose was metabolized to nonabsorbable compounds in the intestine. The mean total plasma clearance was 294 +/- 57 ml/min, of which renal clearance, metabolic clearance, and gastrointestinal and/or biliary clearance were responsible for 165 +/- 31, 31 +/- 15, and 95 +/- 32 ml/min, respectively. The half-life of the terminal phase determined from plasma levels up to 24 hr after dosing was 3.1 +/- 0.3 hr for the iv dose and 6.7 +/- 0.7 hr for the oral dose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982773     DOI: 10.1023/a:1015921418245

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption.

Authors:  Y Plusquellec; G Campistron; S Staveris; J Barre; L Jung; J P Tillement; G Houin
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

2.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

3.  The effects of pafenolol and metoprolol on ventilatory function and haemodynamics during exercise by asthmatic patients.

Authors:  C G Löfdahl; G E Marlin; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Dose-dependency in the exsorption of theophylline and the intestinal dialysis of theophylline by oral activated charcoal in rats.

Authors:  K Arimori; M Nakano
Journal:  J Pharm Pharmacol       Date:  1988-02       Impact factor: 3.765

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

6.  Elimination of drugs by active intestinal transport.

Authors:  C F George; B S Gruchy
Journal:  J Pharm Pharmacol       Date:  1979-09       Impact factor: 3.765

7.  Monitoring 24-hour blood pressure in a drug trial. Evaluation of a noninvasive device.

Authors:  G Berglund; U De Faire; J Castenfors; G Andersson; M Hartford; H Liedholm; S Ljungman; T Thulin; J Wikstrand
Journal:  Hypertension       Date:  1985 Sep-Oct       Impact factor: 10.190

8.  Pafenolol, a highly selective beta 1-adrenoceptor-antagonist, in asthmatic patients: interaction with terbutaline.

Authors:  C G Löfdahl; G E Marlin; N Svedmyr
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

9.  Pafenolol, a new beta 1-selective blocking agent, in mild hypertension. Result of an inpatient study and a subsequent outpatient follow-up.

Authors:  J A Sigurdsson; C Bengtsson; T Bjurö
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Penicillamine kinetics in normal subjects.

Authors:  R F Bergstrom; D R Kay; T M Harkcom; J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

View more
  6 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Absorption and disposition of a new antiarrhythmic agent bidisomide in man.

Authors:  C S Cook; G B Ames; M E Smith; K G Kowalski; A Karim
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

3.  Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

4.  Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

5.  Pharmacokinetics of a novel antiarrhythmic drug, actisomide.

Authors:  C S Cook; L F Rozek; J Stolzenbach; S Anderson; G L Schoenhard; A Karim
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

6.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.